Replaces Prod. #: BML-CC202
Inhibitor of CDK1/cyclin B (IC50=2µM) and CDK5/p35 (IC50=3µM). Similar to olomoucine, but more potent.
Product Specification
| Alternative Name: | 6-Benzylamino-2-(2-hydroxyethylamino)-9-Isopropylpurine |
| |
| Formula: | C17H22N6O |
| |
| MW: | 326.4 |
| |
| CAS: | 158982-15-1 |
| |
| Purity: | ≥98% (HPLC, TLC) |
| |
| Appearance: | White to off-white crystalline solid. |
| |
| Solubility: | Soluble in DMSO or dimethyl formamide; sparingly soluble in methanol. |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stock solutions are stable for 3 months when stored at -20°C. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis: F.I. Raynaud, et al.; Mol. Cancer Ther.
3, 353 (2004),
Abstract;
Inhibition of cyclin-dependent kinases by purine analogues: J. Vesely, et al.; Eur. J. Biochem.
224, 771 (1994),
Abstract;
